Sporadic epithelial ovarian cancer: Clinical relevance of brca1 inhibition in the DNA damage and repair pathway

Journal of Clinical Oncology

Volumn 26, Issue 19, 2008, Pages 3259-3267

  Weberpals, Johanne I ^a   Clark Knowles, Katherine V ^a   Vanderhyden, Barbara C ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; TUMOR MARKER; TUMOR PROTEIN;

ADJUVANT THERAPY; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SCREENING; CARCINOGENESIS; CELL CYCLE ARREST; CLINICAL TRIAL; DNA DAMAGE; DNA METHYLATION; DNA MICROARRAY; DNA REPAIR; FAMILIAL CANCER; GENE CONTROL; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE INTERACTION; GENE TARGETING; GENE THERAPY; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; RETROVIRUS; REVIEW; SOMATIC MUTATION; SPORADIC EPITHELIUM OVARY CANCER; FEMALE; GENETICS; MUTATION; OVARY TUMOR; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

DNA DAMAGE; DNA REPAIR; FEMALE; GENES, BRCA1; GERM-LINE MUTATION; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS;

EID: 49249138928     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.3902     Document Type: Review

References (113)

1. Boyd J: Molecular genetics of hereditary ovarian cancer. Oncology (Williston Park) 12:399-406, 1998
2. Risch HA, McLaughlin JR, Cole DE, et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710, 2001
3. Matloff ET: The breast surgeon's role in BRCA1 and BRCA2 testing. Am J Surg 180:294-298, 2000
4. Yoshida K, Miki Y: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95:866-871, 2004
5. Kennedy RD, Quinn JE, Johnston PG, et al: BRCA1: Mechanisms of inactivation and implications for management of patients. Lancet 360:1007-1014, 2002
6. Bochar DA, Wang L, Beniya H, et al: BRCA1 is associated with a human SWI/SNF-related complex: Linking chromatin remodeling to breast cancer. Cell 102:257-265, 2000
7. Vaughn JP, Davis PL, Jarboe MD, et al: BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ 7:711-715, 1996
8. Rajan JV, Wang M, Marquis ST, et al: Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A 93:13078-13083, 1996
9. Scully R, Anderson SF, Chao DM, et al: BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 94:5605-5610, 1997
10. Somasundaram K, Zhang H, Zeng YX, et al: Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 389:187-190, 1997
11. Hakem R, de la Pompa JL, Elia A, et al: Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 16:298-302, 1997
12. Kerr P, Ashworth A: New complexities for BRCA1 and BRCA2. Curr Biol 11:R668-R676, 2001
13. Collins N, McManus R, Wooster R, et al: Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 10:1673-1675, 1995
14. Cornelis RS, Neuhausen SL, Johansson O, et al: High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families: The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer 13:203-210, 1995
15. Smith SA, Easton DF, Evans DG, et al: Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 2:128-131, 1992
16. Futreal PA, Liu Q, Shattuck-Eidens D, et al: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122, 1994
17. Berchuck A, Heron KA, Carney ME, et al: Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 4:2433-2437, 1998
18. Hogg R, Friedlander M: Biology of epithelial ovarian cancer: Implications for screening women at high genetic risk. J Clin Oncol 22:1315-1327, 2004
19. Chapman MS, Verma IM: Transcriptional activation by BRCA1. Nature 382:678-679, 1996
20. Monteiro AN, August A, Hanafusa H: Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci U S A 93:13595-13599, 1996
21. Thakur S, Zhang HB, Peng Y, et al: Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 17:444-452, 1997
22. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, et al: Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 5:675-679, 2003
23. Scully R, Chen J, Ochs RL, et al: Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90:425-435, 1997
24. Motoyama N, Naka K: DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev 14:11-16, 2004
25. Venkitaraman AR: Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 114:3591-3598, 2001
26. Scully R, Ganesan S, Vlasakova K, et al: Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 4:1093-1099, 1999
27. Wang Y, Cortez D, Yazdi P, et al: BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14:927-939, 2000
28. Greenberg RA, Sobhian B, Pathania S, et al: Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 20:34-46, 2006
29. Xu B, Kim S, Kastan MB: Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 21:3445-3450, 2001
30. Xu X, Weaver Z, Linke SP, et al: Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3:389-395, 1999
31. Cortez D, Wang Y, Qin J, et al: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286:1162-1166, 1999
32. Yarden RI, Pardo-Reoyo S, Sgagias M, et al: BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30:285-289, 2002
33. Welcsh PL, King MC: BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10:705-713, 2001
34. Reedy MB, Hang T, Gallion H, et al: Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis. Gynecol Oncol 81:441-446, 2001
35. Sylvain V, Lafarge S, Bignon YJ: Dominant-negative activity of a Brca1 truncation mutant: Effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 20:845-853, 2002
36. Chabalier C, Lamare C, Racca C, et al: BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5:1001-1007, 2006
37. Wang RH, Yu H, Deng CX: A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci U S A 101:17108-17113, 2004
38. Bae I, Rih JK, Kim HJ, et al: BRCA1 regulates gene expression for orderly mitotic progression. Cell Cycle 4:1641-1666, 2005
39. Quinn JE, Kennedy RD, Mullan PB, et al: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63:6221-6228, 2003
40. Tassone P, Tagliaferri P, Perricelli A, et al: BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285-1291, 2003
41. Ferguson DO, Alt FW: DNA double strand break repair and chromosomal translocation: Lessons from animal models. Oncogene 20:5572-5579, 2001
42. Jasin M: Chromosome breaks and genomic instability. Cancer Invest 18:78-86, 2000
43. Moynahan ME, Cui TY, Jasin M: Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61:4842-4850, 2001
44. Venkitaraman AR: Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171-182, 2002
45. Hartman AR, Ford JM: BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 32:180-184, 2002
46. Gilmore PM, Quinn JE, Mullan PB, et al: Role played by BRCA1 in regulating the cellular response to stress. Biochem Soc Trans 31:257-262, 2003
47. Roschke AV, Stover K, Tonon G, et al: Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability. Neoplasia 4:19-31, 2002
48. Kristensen GB, Kildal W, Abeler VM, et al: Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol 14:1494-1500, 2003
49. Deng CX, Scott F: Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene 19:1059-1064, 2000
50. Yu VP, Koehler M, Steinlein C, et al: Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 14:1400-1406, 2000
51. Zhou C, Smith JL, Liu J: Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22:2396-2404, 2003
52. DelloRusso C, Welcsh PL, Wang W, et al: Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res 5:35-45, 2007
53. Husain A, He G, Venkatraman ES, et al: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58:1120-1123, 1998
54. Zhou C, Huang P, Liu J: The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochem Biophys Res Commun 336:952-960, 2005
55. Evers B, Jonkers J: Mouse models of BRCA1 and BRCA2 deficiency: Past lessons, current understanding and future prospects. Oncogene 25:5885-5897, 2006
56. Xing D, Orsulic S: A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 66:8949-8953, 2006
57. Clark-Knowles KV, Garson K, Jonkers J, et al: Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 313:133-145, 2007
58. Finch A, Shaw P, Rosen B, et al: Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100:58-64, 2006
59. Xu X, Wagner KU, Larson D, et al: Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22:37-43, 1999
60. Hu Y, Ghosh S, Amleh A, et al: Modulation of aromatase expression by BRCA1: A possible link to tissue-specific tumor suppression. Oncogene 24:8343-8348, 2005
61. Poole AJ, Li Y, Kim Y, et al: Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314:1467-1470, 2006
62. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819, 2004
63. Hosking L, Trowsdale J, Nicolai H, et al: A somatic BRCA1 mutation in an ovarian tumour. Nat Genet 9:343-344, 1995
64. Merajver SD, Frank TS, Xu J, et al: Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1:539-544, 1995
65. Cleton-Jansen AM, Collins N, Lakhani SR, et al: Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer 72:1241-1244, 1995
66. Bozzetti C, Bortesi B, Merisio C: Loss of heterozygosity (LOH) in ovarian cancer. Int J Gynaecol Obstet 85:294-295, 2004
67. Tong D, Kucera E, Schuster E, et al: Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors. Int J Cancer 88:319-322, 2000
68. Baldwin RL, Nemeth E, Tran H, et al: BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res 60:5329-5333, 2000
69. Thrall M, Gallion HH, Kryscio R, et al: BRCA1 expression in a large series of sporadic ovarian carcinomas: A Gynecologic Oncology Group study. Int J Gynecol Cancer 16:166-171, 2006 (suppl 1)
70. Chan KY, Ozcelik H, Cheung AN, et al: Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 62:4151-4156, 2002
71. Hilton JL, Geisler JP, Rathe JA, et al: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94:1396-1406, 2002
72. Zheng W, Luo F, Lu JJ, et al: Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol Oncol 76:294-300, 2000
73. Russell PA, Pharoah PD, De Foy K, et al: Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int J Cancer 87:317-321, 2000
74. Wang C, Horiuchi A, Imai T, et al: Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 202:215-223, 2004
75. Wilcox CB, Baysal BE, Gallion HH, et al: High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159:114-122, 2005
76. Esteller M, Silva JM, Dominguez G, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569, 2000
77. Kato H, Arakawa A, Suzumori K, et al: FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples. Exp Mol Pathol 76:138-142, 2004
78. Werness BA, Parvatiyar P, Ramus SJ, et al: Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. J Natl Cancer Inst 92:1088-1091, 2000
79. Ouchi T, Monteiro AN, August A, et al: BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A 95:2302-2306, 1998
80. Miyoshi Y, Iwao K, Takahashi Y, et al: Acceleration of chromosomal instability by loss of BRCA1 expression and p53 abnormality in sporadic breast cancers. Cancer Lett 159:211-216, 2000
81. Rice JC, Massey-Brown KS, Futscher BW: Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 17:1807-1812, 1998
82. Sourvinos G, Spandidos DA: Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun 245:75-80, 1998
83. Xu CF, Chambers JA, Nicolai H, et al: Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. Genes Chromosomes Cancer 18:102-110, 1997
84. Kass SU, Pruss D, Wolffe AP: How does DNA methylation repress transcription? Trends Genet 13:444-449, 1997
85. Lee MN, Tseng RC, Hsu HS, et al: Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 13:832-838, 2007
86. Scardocci A, Guidi F, D'Alo F, et al: Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer 95:1108-1113, 2006
87. Jeng YM, Cai-Ng S, Li A, et al: Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation. Oncogene 13:6160-6166, 2007
88. Jazaeri AA, Yee CJ, Sotiriou C, et al: Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers J Natl Cancer Inst 94:990-1000, 2002
89. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006
90. Yang Q, Sakurai T, Mori I, et al: Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 92:54-60, 2001
91. Yoshikawa K, Honda K, Inamoto T, et al: Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 5:1249-1261, 1999
92. Thompson ME, Jensen RA, Obermiller PS, et al: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9:444-450, 1995
93. Seery LT, Knowlden JM, Gee JM, et al: BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 84:258-262, 1999
94. Lambie H, Miremadi A, Pinder SE, et al: Prognostic significance of BRCA1 expression in sporadic breast carcinomas. J Pathol 200:207-213, 2003
95. Taron M, Rosell R, Felip E, et al: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13:2443-2449, 2004
96. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195, 2003
97. Boyd J, Sonoda Y, Federici MG, et al: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260-2265, 2000
98. Lafarge S, Sylvain V, Ferrara M, et al: Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20:6597-6606, 2001
99. Bartz SR, Zhang Z, Burchard J, et al: Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 26:9377-9386, 2006
100. Chappuis PO, Goffin J, Wong N, et al: A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 39:608-610, 2002
101. Delaloge SPP, Kloos I: BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. Program and abstracts of the 27th Congress of the European Society for Medical Oncology, Nice, France, October 18-22, 2002 (abstr 120)
102. Goffin JR, Chappuis PO, Begin LR, et al: Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97:527-536, 2003
103. Holt JT, Thompson ME, Szabo C, et al: Growth retardation and tumour inhibition by BRCA1. Nat Genet 12:298-302, 1996
104. Tait DL, Obermiller PS, Redlin-Frazier S, et al: A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 3:1959-1968, 1997
105. Tait DL, Obermiller PS, Hatmaker AR, et al: Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin Cancer Res 5:1708-1714, 1999
106. Lyons J, Bayar E, Fine G, et al: Decitabine: Development of a DNA methyltransferase inhibitor for hematological malignancies. Curr Opin Investig Drugs 4:1442-1450, 2003
107. Shadduck RK, Latsko JM, Rossetti JM, et al: Recent advances in myelodysplastic syndromes. Exp Hematol 35:137-143, 2007
108. Mamon HJ, Dahlberg W, Azzam EI, et al: Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation. Int J Radiat Biol 79:817-829, 2003
109. Harkin DP, Bean JM, Miklos D, et al: Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97:575-586, 1999
110. Kim J, Freeman MR: JNK/SAPK mediates doxorubicin-induced differentiation and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 79:321-328, 2003
111. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005
112. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
113. De Soto JA, Deng CX: PARP-1 inhibitors: Are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? Int J Med Sci 3:117-123, 2006